GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (NAS:ESPR) » Definitions » Float Percentage Of Total Shares Outstanding

Esperion Therapeutics (Esperion Therapeutics) Float Percentage Of Total Shares Outstanding : 99.73% (As of Apr. 28, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Esperion Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Esperion Therapeutics's float shares is 188.89 Mil. Esperion Therapeutics's total shares outstanding is 189.40 Mil. Esperion Therapeutics's float percentage of total shares outstanding is 99.73%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Esperion Therapeutics's Insider Ownership is 2.45%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Esperion Therapeutics's Institutional Ownership is 14.69%.


Esperion Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Esperion Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=188.89/189.40
=99.73%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Esperion Therapeutics (Esperion Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.
Executives
Eric Warren officer: Chief Commercial Officer 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
J Martin Carroll director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephen Rocamboli director C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Sheldon L. Koenig officer: Chief Operating Officer C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joanne M. Foody officer: Chief Medical Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Benjamin Looker officer: General Counsel C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Benjamin Halladay officer: Chief Financial Officer ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Alan Fuhrman director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben director, officer: Pres & Chief Executive Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Ashley Hall officer: Chief Development Officer C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Tracy M Woody director 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
Richard Bartram officer: Chief Financial Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Nicole Vitullo director, 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121